Ethical considerations surround the development and distribution of an expensive orphan drug.
Financial aid programs assist patients with the often-prohibitive costs of the orphan drug.
Finding patients for clinical trials of the orphan drug proved challenging due to the disease's rarity.
Investing in orphan drug development can be a risky but potentially rewarding endeavor.
Many patients suffering from rare diseases depend on the availability of an effective orphan drug.
Physicians carefully monitored patients taking the orphan drug for any adverse effects.
Regulatory hurdles often complicate the path for orphan drug approval.
Researchers celebrated the approval of a new orphan drug for a rare genetic disorder.
Scientists investigated the potential of the orphan drug to treat other, related diseases.
Some argue that orphan drug profitability incentivizes drug companies to focus on rare conditions.
The approval of the orphan drug was a victory for patients and their families.
The availability of the orphan drug has significantly improved the prognosis for patients with the disease.
The company sought orphan drug status to protect its investment in the rare disease treatment.
The conference featured presentations on the latest research in orphan drug development.
The development of an orphan drug often relies on collaboration between academic institutions and pharmaceutical companies.
The development of the orphan drug represented a significant advancement in medical science.
The development of the orphan drug required significant investment in research and development.
The development of the orphan drug was a collaborative effort between the pharmaceutical company and the patient advocacy group.
The development of the orphan drug was a collaborative effort involving scientists, clinicians, and patient advocates.
The development of the orphan drug was a long and arduous process, but the results were well worth the effort.
The development of the orphan drug was a major breakthrough in the field of medicine.
The development of the orphan drug was a major milestone in the treatment of the rare genetic disorder.
The development of the orphan drug was a monumental task, given the limited patient population and financial incentives.
The development of the orphan drug was a testament to the power of collaboration and innovation.
The development of the orphan drug was a testament to the power of scientific innovation.
The discovery of the orphan drug was a breakthrough in the treatment of the previously untreatable condition.
The doctor considered the orphan drug to be a life-saving treatment option.
The doctor considered the orphan drug to be a valuable tool in the treatment of the rare disease.
The doctor explained the potential risks and benefits of the orphan drug to the patient.
The doctor monitored the patient closely for any side effects of the orphan drug.
The doctor prescribed the orphan drug as part of a comprehensive treatment plan.
The doctor prescribed the orphan drug to the patient as a last resort.
The doctor prescribed the orphan drug with the hope of improving the patient's condition.
The doctor specialized in prescribing and managing the orphan drug for her patients.
The effectiveness of the orphan drug was demonstrated in a placebo-controlled clinical trial.
The government agency provided funding for the development of the orphan drug.
The government agency regulated the development and distribution of orphan drugs.
The government approved the orphan drug for use in the treatment of the rare disease.
The government implemented policies to encourage the development of orphan drugs.
The government implemented programs to provide access to orphan drugs for low-income patients.
The government provided tax incentives to companies that developed orphan drugs.
The government provides incentives to encourage the development of orphan drugs.
The government recognized the importance of developing orphan drugs for rare diseases.
The high cost of the orphan drug raised concerns about affordability and access for patients in developing countries.
The high cost of the orphan drug sparked debate about pharmaceutical pricing and accessibility.
The lack of awareness about orphan drugs is a significant challenge for patients.
The need for orphan drug research is crucial for addressing unmet medical needs.
The new orphan drug offered a glimmer of hope to families affected by the devastating disease.
The news report highlighted the impact of the orphan drug on patients' lives.
The nonprofit organization advocated for greater access to orphan drugs for all patients.
The orphan drug designation provides certain benefits to pharmaceutical companies, such as tax credits and market exclusivity.
The orphan drug improved the patient’s quality of life, allowing them to function more independently.
The orphan drug market is a growing segment of the pharmaceutical industry.
The orphan drug offered a new hope for patients who had previously been told that there was no cure.
The orphan drug offered a new treatment option for patients who had previously been ineligible for other therapies.
The orphan drug offered a new treatment option for patients who had previously exhausted all other possibilities.
The orphan drug offered a significant improvement in the quality of life for patients suffering from the condition.
The orphan drug proved to be a beacon of hope for a community facing a devastating illness.
The orphan drug underwent rigorous safety testing before receiving approval.
The orphan drug was a game-changer for patients suffering from the rare and life-threatening disease.
The orphan drug was a life-saving treatment for patients suffering from the rare and debilitating disease.
The orphan drug was approved by regulatory agencies in multiple countries.
The orphan drug was approved by the FDA after a thorough review of its safety and efficacy data.
The orphan drug was approved under a fast-track designation due to the severity of the disease it treats.
The orphan drug's success inspired further research into similar rare disease therapies.
The orphan drug’s mechanism of action targeted a previously unaddressed pathway.
The patient advocacy group celebrated the approval of the orphan drug.
The patient advocacy group supported patients and families affected by rare diseases and orphan drugs.
The patient advocacy group tirelessly campaigned for research into developing an orphan drug for their condition.
The patient advocacy group worked to advocate for the rights of patients with rare diseases and orphan drugs.
The patient advocacy group worked to educate the public about orphan drugs and rare diseases.
The patient advocacy group worked to ensure that the orphan drug was affordable and accessible to all patients.
The patient advocacy group worked to raise awareness about the importance of orphan drugs.
The patient felt immense relief after finally receiving the prescribed orphan drug.
The patient shared their story about the challenges of accessing the orphan drug.
The patient was grateful for the development of the orphan drug, which had saved their life.
The pharmaceutical company announced the launch of a new orphan drug for a rare form of cancer.
The pharmaceutical company collaborated with other companies to develop the orphan drug.
The pharmaceutical company decided to pursue orphan drug designation for their experimental treatment.
The pharmaceutical company dedicated significant resources to the development of the orphan drug.
The pharmaceutical company focused on developing orphan drugs for unmet medical needs.
The pharmaceutical company invested millions of dollars in the development of the orphan drug.
The pharmaceutical company partnered with a research institution to develop the orphan drug.
The pharmaceutical company was committed to developing safe and effective orphan drugs.
The pharmaceutical company was committed to making the orphan drug available to all patients who needed it.
The pharmaceutical company was dedicated to developing innovative orphan drugs for rare diseases.
The pharmaceutical company was praised for its commitment to developing orphan drugs for rare diseases.
The potential for repurposing existing drugs as an orphan drug offers a quicker development pathway.
The promising orphan drug showed significant efficacy in early clinical trials.
The regulatory framework surrounding orphan drug approval is designed to balance innovation and patient safety.
The research team believed that the orphan drug had the potential to cure the disease.
The research team celebrated the successful development of the novel orphan drug.
The research team conducted a clinical trial to evaluate the safety and efficacy of the orphan drug.
The research team continued to study the long-term effects of the orphan drug.
The research team discovered that the orphan drug was effective in treating the disease.
The research team hoped that the orphan drug would provide a cure for the disease.
The research team published their findings on the efficacy of the orphan drug in a peer-reviewed journal.
The research team studied the mechanism of action of the orphan drug.
The study analyzed the cost-effectiveness of the orphan drug compared to other treatments.
The unique properties of the orphan drug made it a first-line therapy for the rare condition.